Determination of Diabetes and Dyslipidemia Goals in the Management of Diabetes

Authors

  • Rajesh Jain Diabetes Prevention Control Project, National Health Mission, India.
  • Susanne Olejas World Diabetes Foundation, Denmark.
  • Sanjeev Davey Muzaffarnagar Medical College, India.
  • Rachna Jain Department of Obstetrics & Gynecology, Jain Hospital, India.
  • Reza Shoghli Department of Cardiology, Azad University of Tehran, Iran.
  • Mohammad Iqbal Consultant Diabetes in Dubai and UK.
  • Seyed Hoseyn Ahmadi Tafti Tehran Heart Centre, Tehran, Iran.
  • Siyamak Jalal hosseini Tehran Heart Centre, Tehran, Iran.

DOI:

https://doi.org/10.9734/bpi/nfmmr/v14/12685D

Keywords:

Type 1 diabetes, type II diabetes, Lipoprotein (LDL), HDL, CVD, dyslipidemia, diabetes, triglyceride, cholesterol, atherosclerosis, hypertension, hypercholesterolemia, mortality, proteinuria, Non-HDL

Abstract

Diabetes Type I and Type II are at Increased Risk for early atherosclerotic CVD, i.e., CHD and PAD [1]; and It is known to us that Glucose control improves TG Level and Cholesterol-lowering has favorable effects on CVD outcomes in T1DM & T2 DM. The primary manifestation of dyslipidemia is the elevation of the total serum cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride concentrations, and lower the high-density lipoprotein (HDL) cholesterol.

Published

2021-08-21

How to Cite

Rajesh Jain, Susanne Olejas, Sanjeev Davey, Rachna Jain, Reza Shoghli, Mohammad Iqbal, … Siyamak Jalal hosseini. (2021). Determination of Diabetes and Dyslipidemia Goals in the Management of Diabetes. New Frontiers in Medicine and Medical Research Vol. 14, 58–64. https://doi.org/10.9734/bpi/nfmmr/v14/12685D

Issue

New Frontiers in Medicine and Medical Research Vol. 14

Section

Chapters